Skip to main content
ASMB
NASDAQ Life Sciences

Assembly Bio Q3 Loss Widens to $20.3M; Gilead $75M Fee Extends Runway Into 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$19.95
Mkt Cap
$410.877M
52W Low
$19.2
52W High
$39.705
52W Position info
3.9% above low
Off High info
50% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

ASMB is trading near its 52-week low of $19.2 (3.9% above the low).

Summary

Assembly Bio posted a $20.3 million Q3 loss as trial costs ramped, but the $75 million Gilead extension fee and $314.3 million cash pile push its runway into 2029 while ABI-6250 advances into Phase 2.


Key Events · Earnings and Guidance · ASMB

  • Q3 Loss Widens on Trial Costs

    Net loss was $20.3 million, or $0.93 per share, versus $9.2 million, or $0.72 per share, a year earlier, driven by R&D of $20.2 million versus $16.6 million as multiple ABI-6250 studies started up.

  • $75M Gilead Fee, Runway to 2029

    Received the first $75 million collaboration extension fee from Gilead in November 2026, which with $314.3 million of cash and marketable securities at September 30 is projected to fund operations into 2029; all outstanding Class B warrants from August 2025 were cancelled.

  • ABI-6250 Phase 2 Dosing Begins

    Dosing started in the Phase 2 study of ABI-6250 in chronic hepatitis delta, and the FDA issued a Study May Proceed letter for a Phase 2 in PBC and PSC, expected to begin in the first quarter of 2027.

  • 40% U.S. Profit Share on HSV Program

    Assembly elected to share 40% of U.S. development costs and profits for the HSV helicase-primase inhibitor program with Gilead, which now leads further development of GS-1179.


Analysis · ASMB · Life Sciences

The headline loss looks bad — $20.3 million versus $9.2 million a year ago — but the quarter's real news is financial durability and pipeline progress. In November, Assembly collected the first $75 million collaboration extension fee from Gilead, which together with $314.3 million of cash and securities at September 30 funds operations into 2029. That removes any near-term financing need, a critical point for a company trading near its 52-week low. On the science side, dosing has begun in the Phase 2 hepatitis delta study of ABI-6250, the FDA cleared the company to run a Phase 2 in cholestatic liver diseases starting in the first quarter of 2027, and Assembly elected to take a 40% U.S. cost-and-profit share on the Gilead HSV program. The higher loss is mostly the cost of standing up multiple clinical trials at once, not a deterioration in the business.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ASMB was trading at $19.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $410.9M. The 52-week trading range was $19.20 to $39.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ASMB - Latest Insights

ASMB
Nov 12, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $20.19
Real-time Price: $19.95 info
Change: -$0.240 (-1%) info
Market Cap: $410.877M info
ASMB
Oct 05, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.79
Real-time Price: $19.95 info
Change: -$2.84 (-12%) info
Market Cap: $410.877M info
ASMB
Sep 08, 2026, 4:49 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.00
Real-time Price: $19.95 info
Change: -$16.05 (-45%) info
Market Cap: $410.877M info
ASMB
Aug 13, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.95
Real-time Price: $19.95 info
Change: -$10.00 (-33%) info
Market Cap: $410.877M info
ASMB
Jun 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.85
Real-time Price: $19.95 info
Change: -$2.90 (-13%) info
Market Cap: $410.877M info